First proficiency testing of second-line anti-tuberculosis drug susceptibility testing in 12 provinces of China

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 11, 2013, Pages 1491-1494

  Jiang, G L ^a   Chen, X ^a   Song, Y ^b   Zhao, Y ^b   Huang, H ^a   Kam, Kai Man ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b DEPARTMENT OF HEALTH   (Hong Kong)

^c Chinese University of Hong Kong   (Hong Kong)

Author keywords

Drug susceptibility testing; Mycobacterium tuberculosis; Proficiency test

Indexed keywords

AMIKACIN; CAPREOMYCIN; KANAMYCIN; OFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHINA; CONTROLLED STUDY; GOOD LABORATORY PRACTICE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

AMIKACIN; ANTITUBERCULAR AGENTS; CAPREOMYCIN; CHINA; DRUG RESISTANCE, BACTERIAL; HUMANS; KANAMYCIN; LABORATORY PROFICIENCY TESTING; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OBSERVER VARIATION; OFLOXACIN; PREDICTIVE VALUE OF TESTS; QUALITY CONTROL; QUALITY INDICATORS, HEALTH CARE; REPRODUCIBILITY OF RESULTS; TUBERCULOSIS;

EID: 84888116599     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0275     Document Type: Article

References (9)

1. Laszlo A, Rahman M, Espinal M, Raviglione M, the WHO/IUATLD Network of Supranational Reference Laboratories. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998. Int J Tuberc Lung Dis 2002; 6: 748-756. (Pubitemid 34988044)
2. Bai G H, Kim S J, Chang C L, et al. Proficiency analysis of drug susceptibility testing by national-level tuberculosis reference laboratories from 1995 to 2003. J Clin Microbiol 2007; 11: 3626-3630. (Pubitemid 350156859)
3. Van Deun A, Wright A, Zignol M, Weyer K, Rieder H L. Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. Int J Tuberc Lung Dis 2011; 15: 116-124.
4. World Health Organization/International Union Against Tuberculosis and Lung Disease Global Working Group on Antituberculosis Drug Resistance Surveillance. Guidelines for surveillance of drug resistance in tuberculosis. WHO/TB/96.210. Geneva, Switzerland. WHO, 1996.
5. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug susceptibility testing, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
6. Kim S J. Drug susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005; 25: 564-569. (Pubitemid 40331189)
7. Pfyffer G E, Bonato D A, Ebrahimzadeh A, et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 1999; 37: 3179-3186. (Pubitemid 29455202)
8. Kam K M, Sloutsky A, Yip C W, et al. Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance. Int J Tuberc Lung Dis 2010; 14: 282-288.
9. Feng Y, Liu S, Wang Q, et al. Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis. PLOS ONE 2013; 8: e55292.